Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.51 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | CHKA | P35790 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3262680 | 0.89 | FUCA1 (0.68) | FUCA1CYP2D6HRH4HRH3S1PR1 | |
| SCHEMBL1565431 | 0.88 | FUCA1 (0.71) | FUCA1ALDH1A1S1PR1S1PR5GBA1 | |
| SCHEMBL28874188 | 0.88 | FUCA1 (0.71) | FUCA1ALDH1A1S1PR1S1PR5GBA1 | |
| Hydrochloric Acid SCHEMBL1245678 | 0.86 | FUCA1 (0.69) | FUCA1ALDH1A1S1PR1S1PR5GBA1 | |
| SCHEMBL24008565 | 0.86 | FUCA1 (0.74) | FUCA1CYP2D6HRH4HRH3S1PR1 | |
| SCHEMBL2268869 | 0.86 | FUCA1 (0.80) | FUCA1CYP2D6HRH4HRH3S1PR1 | |
| SCHEMBL30287840 | 0.86 | FUCA1 (0.74) | FUCA1CYP2D6HRH4HRH3S1PR1 | |
| SCHEMBL1857553 | 0.86 | FUCA1 (0.80) | FUCA1CYP2D6HRH4HRH3S1PR1 | |
| SCHEMBL24023495 | 0.84 | ALDH1A1 (0.82) | ALDH1A1CYP2D6KCNH2CYP2C19CHKA | |
| SCHEMBL24008985 | 0.82 | RAB9A (0.64) | ALDH1A1CYP2D6HRH3KCNH2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
| CN-1324353-A | Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing same | SOD CONSEILS RECH APPLIC (FR) | 2001-11-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | FUCA1 83/4885ALDH1A1 1382/4885CYP2D6 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.